+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether systematic pelvic and para-aortic lymphadenectomy LNE improves overall survival in patients with stage I or II endometrial cancer who have a high risk of recurrence. The trial also looks at how LNE affects disease-free survival, quality of life, complications, side effects, and the number of lymph nodes removed. A total of 640 patients with specific histological types and stages of endometrial cancer will take part in this study. Participants will be randomly assigned to one of two groups. In Arm A, patients will undergo the standard surgical procedure including total hysterectomy and bilateral salpingo-oophorectomy, with an omentectomy added for certain cancer types. In Arm B, patients will receive the same standard surgery plus systematic pelvic and para-aortic lymphadenectomy reaching up to the left renal vein. The study compares these two surgical approaches. Throughout the study, participants will be monitored for overall survival over 60 months. Researchers will also assess disease-free and disease-specific survival at multiple time points up to five years. Serious complications will be recorded during surgery and follow-up visits. Quality of life will be evaluated regularly using standardized questionnaires. The number of lymph nodes removed will be documented during surgery to support the evaluation of treatment impact and safety.

Age: 18Years - 75YearsFEMALEPhase Not Applicable
61 locations
O

Actively Recruiting

Researchers are conducting a prospective, non-interventional study called PETRICHOR in Germany to observe adults with severe chronic rhinosinusitis with nasal polyps CRSwNP whose condition is not well controlled by systemic corticosteroids or surgery. The study focuses on patients newly starting treatment with subcutaneous tezepelumab as part of their routine medical care. Treatment decisions are made between patients and their doctors independently of the study. Participants receive tezepelumab following the European product guidelines during their usual clinical visits. No extra diagnostic or monitoring tests are performed beyond standard care. Data are collected at the beginning and throughout routine visits over a period of up to 104 weeks to understand real-world outcomes. Participants will continue their regular clinical visits during the study, where researchers gather information on symptoms using patient questionnaires like the SNOT-22 and other assessments related to nasal polyps, smell loss, and corticosteroid use. The main focus is the change in sino-nasal symptoms over time. Safety and treatment responses are tracked throughout routine care visits for up to two years.

Age: 18Years - 130YearsAll Genders
19 locations